Disaccharides in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis

Hepatic encephalopathy (HE) is one of the major complications of liver cirrhosis. It has a considerable socioeconomic impact as it reduces the individual’s quality of life and needs repeated admission in hospital for its treatment. HE is a complex neuropsychiatric syndrome, which may complicate acute or chronic liver failure and defined as a disturbance in central nervous system function because of hepatic insufficiency and after exclusion of other brain disease. Traditionally, HE is graded according to the West Haven criteria, which define HE grades I–IV based on the presence of specific clinical signs and symptoms and their severity (1,2). The Working Party proposed a nomenclature of HE and classified into three types : type A, associated with acute liver failure; type B, associated with the existence of porto-systemic communications without intrinsic liver disease; and type C, associated with cirrhosis, which, depending on the manner of presentation, is classified into episodic HE (related to precipitating factors) or spontaneous (persistent HE)(1). However, patients with cirrhosis present with a continuous severity spectrum of neuropsychological symptoms ranging from entire normality (HE 0) up to obvious deficits (3). Even in minimal HE (MHE) without obvious clinical symptoms, neuropsychological and neurophysiological testing uncovers deficits which impact on the quality of life and the fitness to drive a motor vehicle (4-7).In this article we will focus mainly on treatment of HE related to cirrhosis (type-C) using disaccharides.

• Publication year

  2012

• Venue

  Unknown venue

• Publication date

  2012-04-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.5772/29092
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Disaccharides in the treatment of hepatic encephalopathy

  2013cited by this paper
• Miscellanea on Encephalopathies - A Second Look

  2012cited by this paper
• Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: An open labeled randomized controlled trial of lactulose versus no lactulose

  2012cited by this paper
• Prophylaxis of hepatic encephalopathy in acute variceal bleed: A randomized controlled trial of lactulose versus no lactulose

  2011cited by this paper
• What is driving the legal interest in hepatic encephalopathy?

  2011cited by this paper
• A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy

  2011cited by this paper
• Hepatic encephalopathy: from pathophysiology to therapeutic management

  2011cited by this paper
• Rifaximin in the treatment of hepatic encephalopathy

  2011cited by this paper
• Randomised clinical trial: rifaximin improves health‐related quality of life in cirrhotic patients with hepatic encephalopathy – a double‐blind placebo‐controlled study

  2011cited by this paper
• Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy

  2010cited by this paper
• Primary Prophylaxis of Hepatic Encephalopathy in Patients with Cirrhosis: An Open Labeled Randomized Controlled Trial of Lactulose versus No Lactulose: 279

  2010cited by this paper
• Glutamine as a mediator of ammonia neurotoxicity: A critical appraisal.

  2010cited by this paper
• Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy

  2010cited by this paper
• Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.

  2009cited by this paper
• Minimal hepatic encephalopathy is associated with motor vehicle crashes: The reality beyond the driving test

  2009cited by this paper
• Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy

  2009cited by this paper
• Hepatic encephalopathy.

  2009cited by this paper
• Hepatic encephalopathy: pathophysiology and emerging therapies.

  2009influential reference
• Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis

  2009cited by this paper
• An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy

  2008cited by this paper
• Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis

  2008cited by this paper
• Pathogenetic mechanisms of hepatic encephalopathy

  2008cited by this paper
• Aquaporin-4 in hepatic encephalopathy

  2007cited by this paper
• Minimal Hepatic Encephalopathy: A Vehicle for Accidents and Traffic Violations

  2007cited by this paper
• Hospitalizations During the Use of Rifaximin Versus Lactulose for the Treatment of Hepatic Encephalopathy

  2007cited by this paper
• Lactulose improves cognitive functions and health‐related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy

  2007cited by this paper
• Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia

  2007cited by this paper
• Taurine rescues hippocampal long-term potentiation from ammonia-induced impairment.

  2006cited by this paper
• Glutamine: A Trojan horse in ammonia neurotoxicity

  2006cited by this paper
• Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.

  2006cited by this paper
• Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.

  2005cited by this paper
• Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study

  2005cited by this paper
• Ammonia and Hepatic Encephalopathy: The More Things Change, the More They Remain the Same

  2005cited by this paper
• Effect of glutamine synthetase inhibition on astrocyte swelling and altered astroglial protein expression during hyperammonemia in rats.

  2005cited by this paper
• Nonabsorbable disaccharides for hepatic encephalopathy.

  2004cited by this paper
• Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials

  2004cited by this paper
• Glutamine‐induced free radical production in cultured astrocytes

  2004cited by this paper
• Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study.

  2004cited by this paper
• Hypoosmotic swelling increases protein tyrosine nitration in cultured rat astrocytes

  2004cited by this paper
• Functional Imaging of the Brain in Patients with Liver Cirrhosis

  2004cited by this paper
• Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.

  2003cited by this paper
• Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis

  2003cited by this paper
• Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study.

  2003cited by this paper
• Suppression of ammonia‐induced astrocyte swelling by cyclosporin A

  2003cited by this paper
• Hepatic encephalopathy—Definition, nomenclature, diagnosis, and quantification: Final report of the Working Party at the 11th World Congresses of Gastroenterology, Vienna, 1998

  2002cited by this paper
• Ammonia‐induced production of free radicals in primary cultures of rat astrocytes

  2001cited by this paper
• CHRONIC LIVER DISEASES: EPIDEMIOLOGY, PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis

  2001cited by this paper
• Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy

  2001cited by this paper
• The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation.

  2001cited by this paper
• Treatment of hepatic encephalopathy.

  2001cited by this paper
• Efficacy of Lactulose in Cirrhotic Patients with Subclinical Hepatic Encephalopathy

  2000cited by this paper
• The prognostic significance of subclinical hepatic encephalopathy

  2000cited by this paper
• Complications of cirrhosis III. Hepatic encephalopathy.

  2000cited by this paper
• Hepatic Encephalopathy in Liver Cirrhosis

  2000cited by this paper
• Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low-grade cerebral edema?

  2000cited by this paper
• Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: a note of caution

  2000cited by this paper
• Subclinical hepatic encephalopathy impairs daily functioning

  1998cited by this paper
• Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy

  1997cited by this paper
• Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy

  1997cited by this paper
• Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy.

  1995influential reference
• Treatment of porto-systemic encephalopathy with lactitol verus lactulose: a randomized controlled study.

  1995cited by this paper
• Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.

  1993cited by this paper
• Lactitol in treatment of chronic hepatic encephalopathy

  1993cited by this paper
• Rifaximin in the treatment of chronic hepatic encephalopathy.

  1993cited by this paper
• Sodium benzoate in the treatment of acute hepatic encephalopathy: A double‐blind randomized trial

  1992cited by this paper
• Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: Results of a meta‐analysis

  1992cited by this paper
• Cerebral Ammonia Metabolism in Patients with Severe Liver Disease and Minimal Hepatic Encephalopathy

  1991cited by this paper
• [A clinical comparative study of crystalline pure lactulose and powder pure lactitol in portasystemic encephalopathy of cirrhotic patients].

  1991influential reference
• Branched-chain amino acids in hepatic encephalopathy.

  1990cited by this paper
• Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study.

  1989cited by this paper
• Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt

  1989cited by this paper
• Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy.

  1988cited by this paper
• Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: A double‐blind, randomized trial

  1987cited by this paper
• Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal‐systemic encephalopathy: A double‐blind, randomized clinical trial

  1987cited by this paper
• Enterococcus Lactic Acid Bacteria Strain SF68 and Lactulose in Hepatic Encephalopathy: A Controlled Study

  1987cited by this paper
• Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose.

  1985cited by this paper
• The brain in experimental portal‐systemic encephalopathy. I. Morphological changes in three animal models

  1983cited by this paper
• Use of pyridoxine-alpha-ketoglutarate (PAK) in hepatic encephalopathy

  1982cited by this paper
• Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy

  1981cited by this paper
• Selective amono acid solutions in hepatic encephalopathy treatment (a preliminary report).

  1980cited by this paper
• Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy

  1978cited by this paper
• Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial.

  1977cited by this paper
• Comparison of results of long-term treatment of chronic hepatic encephalopathy with lactulose and sorbitol.

  1973influential reference
• A controlled clinical trial of lactulose in hepatic encephalopathy.

  1970influential reference

• No citing papers are available for this paper.